159992 创新药
已收盘 05-26 15:00:00
资讯
新帖
简况
海思科(002653.SZ)：创新药HSK44459乳膏两项新增适应症药物临床试验获批
智通财经 · 41分钟前
海思科(002653.SZ)：创新药HSK44459乳膏两项新增适应症药物临床试验获批
康哲药业(00867)：创新药高选择性TYK2抑制剂CMS-D001获得溃疡性结肠炎适应症和克罗恩病适应症药物临床试验批准通知书
智通财经 · 06:30
康哲药业(00867)：创新药高选择性TYK2抑制剂CMS-D001获得溃疡性结肠炎适应症和克罗恩病适应症药物临床试验批准通知书
千红制药：公司创新药项目均严格按照国家药品注册法规要求推进临床试验
证券之星 · 05-25 16:18
千红制药：公司创新药项目均严格按照国家药品注册法规要求推进临床试验
创新药企陷“生死局”，谁能为“最后一公里”买单？
21世纪经济报道 · 05-25 10:15
创新药企陷“生死局”，谁能为“最后一公里”买单？
转型阵痛中的千红制药：肝素原料药周期冲击业绩，创新药远水难解近渴
市场资讯 · 05-24 15:00
转型阵痛中的千红制药：肝素原料药周期冲击业绩，创新药远水难解近渴
每周股票复盘：中恒集团（600252）回应ST风险及创新药进展
证券之星 · 05-24 04:01
每周股票复盘：中恒集团（600252）回应ST风险及创新药进展
恒瑞医药：2025年公司创新药销售收入163.42亿元
证券日报 · 05-22
恒瑞医药：2025年公司创新药销售收入163.42亿元
海南海药：抗肝纤维化创新药氟非尼酮胶囊III期临床已加速筹备中
证券之星 · 05-22
海南海药：抗肝纤维化创新药氟非尼酮胶囊III期临床已加速筹备中
扬子江药业1类创新药法赞雷生片获批上市，为成人失眠治疗再添新力
21世纪经济报道 · 05-22
扬子江药业1类创新药法赞雷生片获批上市，为成人失眠治疗再添新力
科伦药业（002422）披露子公司在ASCO年会公布多项创新药物研究成果，5月22日股价上涨7.19%
中金财经 · 05-22
科伦药业（002422）披露子公司在ASCO年会公布多项创新药物研究成果，5月22日股价上涨7.19%
海翔药业(002099.SZ)参投公司创新药注射用重组巴曲酶获得药物临床试验批准
智通财经 · 05-22
海翔药业(002099.SZ)参投公司创新药注射用重组巴曲酶获得药物临床试验批准
科伦博泰生物(06990)：于2026年美国临床肿瘤学会年会上公布的多项创新药物研究成果
智通财经网 · 05-22
科伦博泰生物(06990)：于2026年美国临床肿瘤学会年会上公布的多项创新药物研究成果
5月21日昂利康（002940）涨停分析：业绩高增、创新药进展与宠物药放量驱动
证券之星 · 05-21
5月21日昂利康（002940）涨停分析：业绩高增、创新药进展与宠物药放量驱动
港股异动 | 诺诚健华(09969)午后涨超4% 抗炎症创新药ICP054完成首例受试者入组
智通财经 · 05-21
港股异动 | 诺诚健华(09969)午后涨超4% 抗炎症创新药ICP054完成首例受试者入组
创新药迎政策利好 富国港股通医药优选即将结束募集
新浪基金 · 05-21
创新药迎政策利好 富国港股通医药优选即将结束募集
本土创新药企迎收获期：肿瘤守阵地，慢病拓新局
21世纪经济报道 · 05-21
本土创新药企迎收获期：肿瘤守阵地，慢病拓新局
港股创新药、汽车板块携手反弹，港股通科技ETF华夏（159101）价格上扬
证券之星 · 05-21
港股创新药、汽车板块携手反弹，港股通科技ETF华夏（159101）价格上扬
众生药业：昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
证券之星 · 05-20
众生药业：昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
转型阵痛中的千红制药：肝素原料药周期冲击一季度业绩，创新药远水难解近渴
证券之星 · 05-20
转型阵痛中的千红制药：肝素原料药周期冲击一季度业绩，创新药远水难解近渴
华润三九：HiCM-188为全球首个在中、美两国同时获批临床默示许可的基于诱导多能干细胞的心衰再生治疗创新药
证券之星 · 05-20
华润三九：HiCM-188为全球首个在中、美两国同时获批临床默示许可的基于诱导多能干细胞的心衰再生治疗创新药
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.769,"timestamp":1779778995000,"preClose":0.771,"halted":0,"volume":635705544,"delay":0,"changeRate":-0.0026,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.002,"latestTime":"05-26 15:00:00","open":0.768,"high":0.774,"low":0.762,"amount":487000000,"amplitude":0.0156,"askPrice":0.769,"askSize":12051,"bidPrice":0.768,"bidSize":37980,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779845400000},"marketStatusCode":5,"adr":0,"adjPreClose":0.771,"symbolType":"fund","openAndCloseTimeList":[[1779759000000,1779766200000],[1779771600000,1779778800000]],"highLimit":0.848,"lowLimit":0.694,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":-0.270057,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159992","defaultTab":"news","newsList":[{"id":"2638592310","title":"海思科(002653.SZ)：创新药HSK44459乳膏两项新增适应症药物临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2638592310","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638592310?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:31","pubTimestamp":1779784263,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)发布公告，公司于近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，经审查，2026年3月受理的HSK44459乳膏两项新增适应症临床试验申请均符合药品注册的有关要求，同意本品开展临床试验。HSK44459乳膏是公司自主研发的一个全新的具有独立知识产权的治疗银屑病和特应性皮炎的药物。临床前研究结果表明，本品靶点明确、疗效确切、安全性好，是一款极具开发潜力的小分子药物，临床应用的效益/风险比高，具有广阔的临床应用前景，有望成为银屑病和特应性皮炎的有效治疗药物，解决目前临床用药匮乏的难题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06978","159992","BK0033","BK0077","BK0188","BK0239","BK0028","002653","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638568587","title":"康哲药业(00867)：创新药高选择性TYK2抑制剂CMS-D001获得溃疡性结肠炎适应症和克罗恩病适应症药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2638568587","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638568587?lang=zh_cn&edition=full","pubTime":"2026-05-26 06:30","pubTimestamp":1779748246,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，于2026年5月22日，创新药CMS-D001片获得中国国家药品监督管理局签发的药物临床试验批准通知书，于5月25日收到药物临床试验批准通知书。NMPA同意本集团开展临床试验以评价CMS-D001治疗溃疡性结肠炎适应症和克罗恩病适应症的安全性和有效性。目前，CMS-D001健康受试者I期研究已完成，银屑病和特应性皮炎的Ⅱ期临床试验正在开展中，首例受试者已入组。CMS-D001未来还拟开发用于治疗系统性红斑狼疮等自身免疫病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0738911758.USD","SG9999015986.USD","IE00BMCWC346.EUR","00867","LU2346227817.USD","06978","LU0949170772.SGD","LU1894683348.USD","CMS","LU1003077747.HKD","IE00BYV24P56.USD","LU0661504455.SGD","BK4208","BK1161","SG9999015952.SGD","159992","BK1574","IE00BVYPNQ40.USD","LU1894683264.USD","LU2488822045.USD","IE00BVYPNP33.GBP","SG9999004220.SGD","BK4585","SG9999015945.SGD","BK1191","BK1593","IE00BGHQDM52.EUR","SG9999015978.USD","LU0545039389.USD","LU2637428348.USD","LU2500361329.USD","BK4588","LU0553294199.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638535038","title":"千红制药：公司创新药项目均严格按照国家药品注册法规要求推进临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2638535038","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638535038?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:18","pubTimestamp":1779697093,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘请正面回答公司可转债申报阶段是否知道创新药106要进行增补验证？千红制药回复：尊敬的投资者，您好，公司创新药项目均严格按照国家药品注册法规要求推进临床试验，相关进展将依法依规履行披露义务，感谢您的关注。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500021658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","159992","BK1574","BK0239","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638458138","title":"创新药企陷“生死局”，谁能为“最后一公里”买单？","url":"https://stock-news.laohu8.com/highlight/detail?id=2638458138","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638458138?lang=zh_cn&edition=full","pubTime":"2026-05-25 10:15","pubTimestamp":1779675300,"startTime":"0","endTime":"0","summary":"2025年，中国创新药产业交出了一份足以让全球瞩目的成绩单。国家药监局最新数据显示，2025年全年批准上市1类创新药76个品种，大幅超过2024年全年的48个，创历史新高。此外，2025年我国创新药对外授权交易总金额超过1300亿美元，授权交易数量超过150笔，同样创历史新高。我国在研新药管线约占全球30%，位列全球第二。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605253747869762.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605253747869762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159992","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637491308","title":"转型阵痛中的千红制药：肝素原料药周期冲击业绩，创新药远水难解近渴","url":"https://stock-news.laohu8.com/highlight/detail?id=2637491308","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637491308?lang=zh_cn&edition=full","pubTime":"2026-05-24 15:00","pubTimestamp":1779606000,"startTime":"0","endTime":"0","summary":" 作为国内少数涵盖肝素全产业链的生化药企，千红制药在经历了2022年的营收峰值后，连续两年下滑，2025年借低基数实现微弱反弹，却远未恢复至历史高点。进入2026年一季度，出口肝素原料药遭遇全球需求疲软与合同发货周期的双重打击，公司营收与归属净利润再度双双大幅下挫。 证券之星注意到，被千红制药寄予厚望的创新药“第二曲线”仍处于临床阶段，距离商业化贡献业绩尚需时日。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-05-24/doc-inhyytnm5942974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1574","002550","BK0239","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637537543","title":"每周股票复盘：中恒集团（600252）回应ST风险及创新药进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2637537543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637537543?lang=zh_cn&edition=full","pubTime":"2026-05-24 04:01","pubTimestamp":1779566462,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，中恒集团报收于2.21元，较上周的2.26元下跌2.21%。本周，中恒集团5月19日盘中最高价报2.31元。来自公司公告汇总：中恒集团梧州制药（香港）有限公司已完成注销登记。2025年6月13日，中恒集团召开第十届董事会第二十九次会议，审议通过注销中恒集团梧州制药（香港）有限公司的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0015","06978","BK1574","BK0012","BK0188","600252","BK0239","BK0077","159992","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637126963","title":"恒瑞医药：2025年公司创新药销售收入163.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637126963","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637126963?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:59","pubTimestamp":1779454740,"startTime":"0","endTime":"0","summary":"证券日报网讯5月22日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持科技创新战略，已在中国获批上市24款1类创新药、5款2类新药，另有100多个自主创新产品正在临床开发，400余项临床试验在国内外开展。经营业绩方面，创新成果转化高效赋能，创新药销售引领业绩增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223747010910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","LU1997245094.SGD","06978","LU1580142542.USD","LU2097828714.EUR","LU2328871848.SGD","LU2580892862.HKD","LU1146622755.USD","LU1969619763.USD","LU2580892789.USD","LU0359201612.USD","BK1191","BK0012","LU0359202008.SGD","LU1655091616.SGD","LU1328615791.USD","LU2097828557.USD","600276","LU0359201885.HKD","LU2289578879.USD","LU2495084118.USD","LU2543165471.USD","LU1064131003.USD","01276","LU0405327494.USD","159992","BK0183","LU1064130708.USD","LU2097828474.EUR","BK1574","LU0405327148.USD","BK0239","BK0060","LU1997244956.HKD","LU2488822045.USD","LU1820825898.SGD","LU1023057109.AUD","BK0188","BK0196","LU1781817850.SGD","LU2148510915.USD","LU2097828805.USD","LU1997245177.USD","BK1161","LU1255011170.USD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637231490","title":"海南海药：抗肝纤维化创新药氟非尼酮胶囊III期临床已加速筹备中","url":"https://stock-news.laohu8.com/highlight/detail?id=2637231490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637231490?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:48","pubTimestamp":1779454113,"startTime":"0","endTime":"0","summary":"证券之星消息，海南海药05月21日在投资者关系平台上答复投资者关心的问题。公司紧盯创新药核心突破，持续加码两款创新药研发投入，全速推进临床试验进程，公司抗肝纤维化创新药氟非尼酮胶囊III期临床已加速筹备中。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200042257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","06978","BK0060","BK0146","000566","BK0239","159992","BK0070","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637631572","title":"扬子江药业1类创新药法赞雷生片获批上市，为成人失眠治疗再添新力","url":"https://stock-news.laohu8.com/highlight/detail?id=2637631572","media":"21世纪经济报道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637631572?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:40","pubTimestamp":1779446400,"startTime":"0","endTime":"0","summary":"日前，国家药品监督管理局发布信息：批准江苏海岸药业有限公司申报的1类创新药法赞雷生片（商品名：孟平）上市，用于治疗以入睡困难和/或睡眠维持困难为特征的成人失眠患者。睡眠健康事关全民身心健康与生活质量。当前，失眠障碍已成为高发慢性疾病，长期困扰着广大人群，易引发情绪、认知、代谢等多系统健康问题，临床对安全有效、依从性佳的新型治疗药物需求迫切。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605223746895123.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223746895123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06978","IPOS","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637133913","title":"科伦药业（002422）披露子公司在ASCO年会公布多项创新药物研究成果，5月22日股价上涨7.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637133913","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637133913?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:03","pubTimestamp":1779444189,"startTime":"0","endTime":"0","summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}table{border-collapse:collapse;}table,th,td{border: 1px solid black;}.article_content ul{padding-left:22px;}截至2026年5月22日收盘，科伦药业报收于34.72元，较前一交易日上涨7.19%，最新总市值为552.32亿元。该股当日开盘33.57元，最高35.57元，最低33.57元，成交额达13.46亿元，换手率为2.98%。近日，科伦药业发布公告称，其控股子公司科伦博泰将在2026年美国临床肿瘤学会年会上公布多项创新药物研究成果。两项研究数据支持的相关上市申请已获NMPA受理。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202605/22/20260522583175.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202605/22/20260522583175.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260522/32247397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","LU1979443071.USD","LU1064130708.USD","002422","LU2148510915.USD","LU1934453819.USD","BK0060","LU1064131003.USD","BK1574","06978","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637391887","title":"海翔药业(002099.SZ)参投公司创新药注射用重组巴曲酶获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637391887","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637391887?lang=zh_cn&edition=full","pubTime":"2026-05-22 15:45","pubTimestamp":1779435906,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业 发布公告，公司近日收到旗下产业基金管理人北京国信中数投资管理有限公司出具的《通知函》。公司获悉北京国信海翔股权投资合伙企业参投公司北京格瑞特森生物医药科技有限公司自主研发的创新生物药注射用重组巴曲酶收到国家药品监督管理局正式核发的《药物临床试验批准通知书》，同意本品开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","159992","002099","BK0192","06978","BK0077","BK1161","BK1574","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637728368","title":"科伦博泰生物(06990)：于2026年美国临床肿瘤学会年会上公布的多项创新药物研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2637728368","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637728368?lang=zh_cn&edition=full","pubTime":"2026-05-22 07:36","pubTimestamp":1779406592,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物 发布公告，本公司将在于2026年5月29日至6月2日于美国伊利诺伊州芝加哥市举行的2026年美国临床肿瘤学会年会上公布多项公司主导的临床研究成果，其中靶向人滋养细胞表面抗原2抗体偶联药物芦康沙妥珠单抗(佳泰莱)、新一代选择性转染过程中重排抑制剂富马酸仑博替尼两项注册研究入选转移性非小细胞肺癌口头报告专场。上述研究的完整摘要已于当地时间2026年5月21日发布在ASCO的官方网站上。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06990","BK1161","159992","LU0196878994.USD","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637388893","title":"5月21日昂利康（002940）涨停分析：业绩高增、创新药进展与宠物药放量驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2637388893","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637388893?lang=zh_cn&edition=full","pubTime":"2026-05-21 15:33","pubTimestamp":1779348831,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康5月21日涨停收盘，收盘价45.65元。5月21日昂利康涨停的可能因素有：2025年归母净利润同比大增56.15%、扣非净利增78.82%，核心制剂业务营收增长超20%；定增11.2亿元获深交所受理，全部投向创新药ALK-N001Ⅰ期临床；富马酸伏诺拉生片获批双规格注册证书；宠物麻醉药批文落地且销量倍增；头孢全酶法工艺及阿莫西林技改强化原料药一体化能力。近5日资金流向一览见下表：该股为创新药，医药，化学原料药概念热股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100023617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","002940","06978","BK1574","159992","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637041198","title":"港股异动 | 诺诚健华(09969)午后涨超4% 抗炎症创新药ICP054完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2637041198","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637041198?lang=zh_cn&edition=full","pubTime":"2026-05-21 14:03","pubTimestamp":1779343431,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华午后涨超4%，截至发稿，涨3.27%，报12.32港元，成交额9032.58万港元。消息面上，诺诚健华此前发布公告，新型口服、潜在同类最佳的IL-17AA/AF抑制剂 ICP-054 的1期临床试验完成首例受试者入组。目前，全球尚无口服IL-17抑制剂获批上市或处于后期开发阶段。ICP-054的口服小分子特性，在用药便利性、患者依从性以及临床可及性上，有潜力比目前已获批的生物制剂IL-17疗法更具优势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","06978","BK1161","09969","BK4585","VXUS","BK1574","BK4588","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637806569","title":"创新药迎政策利好 富国港股通医药优选即将结束募集","url":"https://stock-news.laohu8.com/highlight/detail?id=2637806569","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637806569?lang=zh_cn&edition=full","pubTime":"2026-05-21 11:58","pubTimestamp":1779335880,"startTime":"0","endTime":"0","summary":"近期，中国创新药出海再添重磅利好，恒瑞医药与BMS达成总金额约152亿美元的全球战略合作，标志着国内创新药从“出海授权”迈入“全球共创”新周期；与此同时，港版FDA计划于年底成立，内地医保目录调整同步提速，创新药产业迎来多重利好。在此背景下，富国港股通医药优选混合型证券投资基金正在发行中，并将于5月22日结束募集。该基金专注港股医药赛道，为投资者布局港股创新药龙头提供便捷通道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-05-21/doc-inhyrrtp6358211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","159938","BK1161","BK1574","159992","BK4588","09939","BK4585","06978","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380651","title":"本土创新药企迎收获期：肿瘤守阵地，慢病拓新局","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380651","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637380651?lang=zh_cn&edition=full","pubTime":"2026-05-21 11:47","pubTimestamp":1779335272,"startTime":"0","endTime":"0","summary":"当前，我国创新药产业在BD（商务拓展）出海与本土商业化放量的驱动下，产业结构加速优化，本土创新药从研发投入期转向价值收获期。日前，药智网数据显示，2025年国内创新药销售收入TOP10药企合计营收突破千亿元大关。百济神州、恒瑞医药、中国生物制药、翰森制药、信达生物迈过创新药收入百亿元门槛。同时，百济神州、信达生物更是实现扭亏为盈，打破“国产创新药只烧钱不赚钱”的魔咒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605213744749076.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605213744749076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637980869","title":"港股创新药、汽车板块携手反弹，港股通科技ETF华夏（159101）价格上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2637980869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637980869?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:03","pubTimestamp":1779329019,"startTime":"0","endTime":"0","summary":"5月21日(周四)早盘，港股汽车、港股创新药板块携手反弹。截至9:57，港股通科技ETF华夏二级市场价格上扬，持仓股小鹏集团-W涨超6%，康方生物涨超5%，信达生物、百济神州涨超2%。逢低关注新一代港股科技底仓配置工具——港股通科技ETF华夏，被动跟踪国证港股通科技指数，覆盖硬科技+互联网+新能源汽车+生物科技，充分受益于AI产业趋势、“十五五”制造升级与数字中国双重映射、创新药出海浪潮。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026052100013011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","159992","159101","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636847667","title":"众生药业：昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2636847667","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636847667?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:53","pubTimestamp":1779281599,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)05月20日在投资者关系平台上答复投资者关心的问题。投资者提问：已经26年5月了，怎么看不到贵公司昂拉地韦片25年销量？股民有权知道25年每月销量吗？26年1季度销量能公布吗？众生药业回复：您好！昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药，适用于成人单纯性甲型流感患者的治疗，销售与流感季节性相关。公司正持续推进学术推广与渠道建设，后续将结合流感周期与医保落地效应，稳步推动昂拉地韦片的商业化工作。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000041340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1161","06978","002317","BK0077","BK1574","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636581718","title":"转型阵痛中的千红制药：肝素原料药周期冲击一季度业绩，创新药远水难解近渴","url":"https://stock-news.laohu8.com/highlight/detail?id=2636581718","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636581718?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:00","pubTimestamp":1779267644,"startTime":"0","endTime":"0","summary":"进入2026年一季度，出口肝素原料药遭遇全球需求疲软与合同发货周期的双重打击，公司营收与归属净利润再度双双大幅下挫。2023年财报中，千红制药曾坦言，肝素原料药面临下游企业去库存、需求大幅下滑导致出口价格与数量均显著下降，行业整体受到较大冲击。对于肝素主业与创新药业务之间的战略重心如何平衡，千红制药回应称，未来将加大重大创新药物的研发与上市节奏，使之成为公司业务增长的新的战略核心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026052000030426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","002550","06978","BK1161","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636814129","title":"华润三九：HiCM-188为全球首个在中、美两国同时获批临床默示许可的基于诱导多能干细胞的心衰再生治疗创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2636814129","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636814129?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:12","pubTimestamp":1779264739,"startTime":"0","endTime":"0","summary":"从新闻得知华润三九大举进军CGT，与深圳三院共建CGT联合实验室，打通医企研全链条转化路径，加速细胞与基因治疗产业化。华润三九积极布局细胞与基因治疗领域，已有多个在研管线，天士力已有3项CGT药物现已处于临床I期阶段，公司达成HiCM-188 项目联合研发合作，HiCM-188 为全球首个在中、美两国同时获批临床默示许可的基于诱导多能干细胞的心衰再生治疗创新药，助力公司进一步拓展细胞治疗赛道，更好地满足终末期心衰临床需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000028293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0060","000999","BK0196","BK0010","BK0028","BK1161","BK0188","BK0175","BK0185","BK0239","BK0183","159992","BK0012","06978"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779786711677,"stockEarnings":[{"period":"1week","weight":-0.0166},{"period":"1month","weight":-0.0677},{"period":"3month","weight":-0.0688},{"period":"6month","weight":-0.1268},{"period":"1year","weight":0.0065},{"period":"ytd","weight":-0.0722}],"compareEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":0.0178},{"period":"3month","weight":0.0085},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.2402},{"period":"ytd","weight":0.0463}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}